Abstract: *Panax quinquefolius*, a popular medicinal herb, has been cultivated in China for many years. In this work, the region-specific profiles of metabolites in *P. quinquefolius* from Wendeng was investigated using liquid-chromatography–quadrupole–time-of-flight-(LC–Q–TOF)-based metabolomics analysis. The three most abundant biomarkers, identified as ginsenoside Rb$_3$, notoginsenoside R$_1$, and ginsenoside Rc, were the representative chemical components employed in the network pharmacology analysis. In addition, molecular docking and western blotting analyses revealed that the three compounds were effective binding ligands with Hsp90, resulting in the inactivation of SRC and PI3K kinase, which eventually led to the inactivation of the Akt and ERK pathways and lung cancer suppression. The outcomes obtained herein demonstrated the intriguing chemical characteristics and potential functional activities of *P. quinquefolius* from Wendeng.

Keywords: *Panax quinquefolius*; biomarkers; network pharmacology; molecular docking; protein phosphorylation

1. Introduction

*Panax quinquefolius* L. (American ginseng) is a well-known traditional herbal medicine with a large demand on the Asian market. Its extracts have also become popular in the US and Europe as dietary health supplements and additives to foods and beverages. The key constituents of the herb include ginsenosides, polysaccharides, peptides, polyacetylenes, and phenols. However, the contents of *P. quinquefolius* are influenced by biological and environmental factors [1–6]. Numerous studies have investigated ginsenosides, and the total amount of these natural products (i.e., Rg$_1$, Rb$_1$, or Re) is used as an index to evaluate the quality of ginseng. Modern pharmacological studies have shown that *P. quinquefolius* plays a role in regulating the immune system and exhibits antitumor, anti-diabetic, anti-inflammatory, and antioxidant effects, as well as protective effects on cardiovascular and cerebrovascular systems [7–12].

*P. quinquefolius* mainly grows in the USA and Canada in the wild and was introduced into China in the last century. In 1964, *P. quinquefolius* was introduced into Wendeng county (122.22° E, 37.25° N), which has become one of the major cultivation areas in China [13]. It is widely recognized that the biological activities of medicinal plants result from the presence of various chemical constituents. Although systematic studies of the components of *P. quinquefolius* have been conducted, and the ages of roots and other parts of the plant
have been examined [14–19], so far, the medicinal potency of the *P. quinquefolius* cultivated in Wendeng has not been analyzed. Further studies are needed to elucidate the differences in its application and efficacy, despite its overlapping therapeutic indications with the North America species.

Oomics-based approaches have been widely employed to study variations in the primary and secondary metabolites in plants. Metabolomics, a relatively new discipline developed after genomics and proteomics, can be used to investigate the changes in the entire metabolic network of an organism and has in recent years attracted considerable attention [20–23]. Liquid chromatography–mass spectrometry (LC–MS) is a commonly utilized technique in metabolomics-based analysis. Furthermore, network pharmacology is an emerging field, which combines multidimensional information on a “compound–target–disease” and establishes a visualization network to understand the therapeutic effects of a substance [24–26]. The above methods can be employed to study the relationships between molecules and diseases. Notably, they can be used simultaneously to investigate active mechanisms based on complex biological systems.

Lung cancer is the most common form of cancer in the world and is the leading cause of cancer-related death. Thus, the development of practical and efficacious therapies for the treatment of the disease is important [27,28]. In this work, metabolomics coupled with network pharmacology was used to evaluate region-specific biomarkers of *P. quinquefolius* from Wendeng. The identified compounds were comprehensively screened and predominantly enriched in cancer-associated pathways, and the mechanisms of the natural products in the treatment of lung adenocarcinoma were then studied. Finally, molecular docking and western blotting analyses were conducted to verify the key targets—i.e., those which exhibited the highest correlation with the disease.

2. Results

2.1. Statistical Analysis and Biomarker Discovery

The metabolites of *P. quinquefolius* were investigated using liquid-chromatography–quadrupole–time-of-flight–mass spectrometry–time-of-flight (LC–Q–TOF–MS–TOF)-based methods (Figures S1–S4). A total of 371 primary metabolites were extracted using the R software package in the negative mode. The metabolomic profiles of *P. quinquefolius* grown in Wendeng, Yanbian, Ontario, and Wisconsin are shown as heatmaps in Figure 1A. The obtained heatmaps clearly indicated the relative abundances of the major metabolites in the four groups of samples. To highlight the disparities in the metabolites in the Wendeng species, principal component analysis (PCA) and orthogonal projections to latent structures discriminant analysis (OPLS-DA) were used to classify and discriminate the data. The scores plot yielded a distinct degree of variation between the samples (Figure 1B), suggesting that the metabolic profiles were dissimilar. The values of $R^2 = 0.661$ and $Q^2 = 0.517$, which represent the quality of fit and predictability, respectively, indicated the reliability of the model [29]. The variables with the VIP values of >1, $p$-values of <0.05, and $p$ (corr) of <0.5 were considered to significantly contribute to the separation in the S-plots. Moreover, 42 (Yanbian species), 49 (Ontario species), and 43 (Wisconsin species) metabolites were viewed as potential markers (Figure 1C–E). Furthermore, following omics-based analyses, 30 overlapped metabolites were identified as biomarkers of *P. quinquefolius* cultivated in the Wendeng region (Table S1).
Figure 1. Metabolic profiling of *P. quinquefolius* grown in four different regions. (A) Heatmap showing the relative abundance values of all metabolites; (B) PCA analysis; (C) OPLS-DA plots of the Wendeng and Yanbian species; (D) OPLS-DA plots of the Wendeng and Ontario species; (E) OPLS-DA plots of the Wendeng and Wisconsin species.

The three most abundant biomarkers were identified as ginsenoside Rb$_3$ (1, 13.2 min), notoginsenoside R$_1$ (2, 16.5 min), and ginsenoside Rc (3, 18.3 min) (Figure 2). In the electrospray ionization–tandem mass spectrometry (ESI–MS/MS) spectra, ginsenoside Rb$_3$ exhibited a quasi-molecular ion peak $[M – H − H_2O]^{-}$ at $m/z$ 1059.5312 with its daughter ions at $m/z$ 945 $[M – H − Xyl]^{-}$ and $m/z$ 478 $[Aglycone + Cl]^{-}$. The spectrum of notoginsenoside R$_1$ displayed a quasi-molecular ion peak $[M – H − H_2O]^{-}$ at $m/z$ 913.4771 and the corresponding double-charged fragment ion at $m/z$ 317 $[M − 2H − Xyl − Glc]^{-}$. Lastly, the spectrum of ginsenoside Rc showed a signal corresponding to the $[M − H − H_2O]^{-}$ ion at $m/z$ 1059.5344 as the base peak. Additionally, ginsenoside Rc’s fragment ions were detected at $m/z$ 947.5664 $[M − H − Ara]^{-}$ and $m/z$ 622.7268 $[M − H − Ara − 2Glc]^{-}$. All peaks were identified through a comparison with the literature data and were further confirmed by the LC–MS analysis of the reference compounds (Figure S5).

2.2. Construction and Analysis of Interaction Networks

After removing redundant entries, 157 protein targets of the three natural products (i.e., ginsenoside Rb$_3$, notoginsenoside R$_1$, and ginsenoside Rc) were identified and transformed into gene IDs using the Uniprot database (http://www.uniprot.org/, accessed on 2 July 2020). Based on the “count” values, a KEGG enrichment analysis indicated that the top pathway was related to cancers (Figure 3A and Table S2). A GAD disease enrichment analysis revealed that these targets were significantly associated with breast, lung, prostate, bladder, and colorectal cancers, as well as with esophageal adenocarcinoma (Figure 3B).

A total of 274 lung-adenocarcinoma-related genes were obtained using GeneCards to construct a disease-target database. After merging the active compound and disease targets, a PPI network was established by linking the compounds and proteins if they shared one or more target proteins. The visualized network system is illustrated in Figure S6, which suggested the presence of interactions between the molecules and proteins. The degree of each node was defined as the number of edges connected to it and indicated the importance of the node in the network. A topological analysis revealed that HSP90AA1 was an important binding target of the examined compounds. It was determined that HSP90AA1 hit downstream genes SRC, PIK3CA, and PIK3R1 to modulate lung cancer progression (Table S3).
Figure 2. MS and MS/MS spectra of the biomarkers identified in *P. quinquefolius* from Wendeng: (A) ginsenoside Rb3; (B) notoginsenoside R1; (C) ginsenoside Rc.

Figure 3. KEGG pathway (A) and GAD disease (B) enrichment analysis for the analyzed natural products.

2.3. Docking Results Analysis

Heat shock protein 90α (Hsp90α; HSP90AA1) is a molecular chaperone, which facilitates the correct folding and functionality of its client proteins, predominantly kinases and the nuclear receptors involved in cellular signaling, proliferation, and cell survival. The docking results obtained herein provide a detailed overview of the ligand-receptor interactions. Specifically, ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were confirmed to be effective binding ligands with Hsp90α (Figure 4). Among the three compounds, notoginsenoside R1 exhibited the lowest binding free energy (ΔG bonded —3.09 kcal/mol) and formed five hydrogen bonds with the Gly-132 (1.8 Å), Gly-135 (2.8 and 2.4 Å), Asn-106 (2.2 Å), and Asp-54 (2.6 Å) residues of the protein. Thus notoginsenoside R1 displayed the highest potential affinity with the binding site. The binding energy calculation results for the investigated compounds are summarized in Table S4. Based on the analysis of the molecular interactions, the binding activity of ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc with respect to Hsp90α could lead to anticancer activity.
pounds, notoginsenoside R1, and ginsenoside Rc with respect to Hsp90α could lead to anticancer activity.

2.3. Docking Results Analysis

The docking results obtained herein provide a detailed overview of the ligand–receptor interactions. Specifically, ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were confirmed to be effective binding ligands with Hsp90α (Fig. 4). Among the three compounds, ginsenoside Rc exhibited the lowest binding free energy (ΔG = -3.09 kcal/mol), indicating the highest potential affinity with the binding site. The binding energy calculation results for the investigated compounds are summarized in Table S4.

2.4. Phosphorylation of SRC, PI3Kα, Akt, and ERK

The steroid receptor coactivator (SRC) is overexpressed in many cancer types. The PIK3CA and PIK3R1 genes encode for phosphoinositide 3-kinase (PI3K) p110α and p85α subunits, which are regulators critical to the cell’s survival. In this study, ginsenoside Rc, ginsenoside Rb3, and notoginsenoside R1 clearly inhibited the proliferation of the A549 cells, with >50% inhibition rates at 2.5, 2, and 1 mM, respectively (Table 1). To validate our bioinformatics analysis, western blotting was performed to determine the relationships between the compounds and the modified expressions of different proteins in the A549 cells, which led to growth inhibition.

Table 1. MTT assay in A549 cells.

| Concentrations | Cells Viability |
|----------------|----------------|
|                | Ginsenoside Rc | Ginsenoside Rb3 | Notoginsenoside R1 |
| 0.1 mM         | 92.05%         | 87.24%          | 86.40%             |
| 0.5 mM         | 91.41%         | 78.58%          | 65.91%             |
| 1 mM           | 75.33%         | 72.22%          | 42.73%             |
| 1.5 mM         | 72.04%         | 64.27%          | 14.24%             |
| 2 mM           | 59.84%         | 43.01%          | 4.52%              |
| 2.5 mM         | 49.18%         | 24.11%          | 1.50%              |
| 3 mM           | 40.53%         | 1.66%           | 0.61%              |

A significant decrease in the protein levels was observed at the above concentrations. The phosphorylation of SRC was almost completely blocked by ginsenoside Rb3 and notoginsenoside R1. In addition, the phosphorylation of PI3K was significantly inhibited by all three compounds, particularly by ginsenoside Rb3 and notoginsenoside R1. In contrast, the levels of total SRC and PI3K were not affected (Figure 5A,B). Akt and ERK are the key downstream effectors of SRC and PI3K, and have been considered important factors contributing to the survival of tumor cells. Notably, decreased levels of phosphorylated Akt were found in the A549 cells following treatment with the investigated compounds. Moreover, the ERK phosphorylation was also significantly inhibited by notoginsenoside R1 (Figure 5C,D). The acquired data confirms that ginsenoside Rc, ginsenoside Rb3, and notoginsenoside R1 affected the levels of SRC and PI3K in the cells. Inactivation of SRC and PI3K by the studied compounds affected the downstream Akt and ERK signaling pathways, leading to A549 cell death.
Reduced, and PCA and OPLS-DA were conducted to highlight the metabolite disparities cultivated in the Wendeng region. Heatmaps were produced, and PCA and OPLS-DA were conducted to highlight the metabolite disparities between the *P. quinquefolius* originating from four production areas. Ginsenosides were previously recognized as the primary bioactive components in the root of *P. quinquefolius* [30,31]. According to the LC–MS/MS analysis, ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were the most abundant biomarkers in the Wendeng species. Moreover, the KEGG pathway and GAD disease enrichment analyses indicated that the compounds were predominantly enriched in lung-cancer-associated pathways. Potential associations between HSP90AA1 (the drug target) and SRC, PIK3CA, and PIK3R1 (the disease targets) were discovered through integrated network pharmacology.

Hsp90 inhibitors exert their inhibitory effects by competitively binding at the ATP binding site of the Hsp90 dimer. They interfere with diverse signaling pathways by destabilizing and attenuating the activity of proteins and are selectively toxic to tumor cells [32,33]. Aberrant activation of the Akt pathway is observed in various human cancers. This activation plays a prominent role in various events associated with tumor progression, such as cell proliferation, invasion, migration, and adhesion [34–36]. Moreover, the Akt pathway is found to cross talk with the MAPK pathway. Previous studies demonstrated that activated SRC recruits the p85 subunit of PI3K, which results in the activation of PI3K and eventually the activation of Akt and extracellular-signal-regulated kinase (ERK) [37]. Thus, it is speculated that phytochemicals inhibiting the phosphorylation of SRC and PI3K could be promising therapeutics for the treatment of lung cancer. Molecular docking and western blotting results reveal that ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were effective binding ligands with Hsp90α and inactivated SRC and PI3K kinase. The interactions between the compounds and the proteins led to the inhibition of the Akt and ERK signaling pathways, which resulted in tumor cell apoptosis.

China has a long history of botanical drug use. According to prior reports, *P. quinquefolius* from Wisconsin (USA) and Ontario (Canada) has been recorded as a “genuine regional drug”. Yanbian is the traditional planting region in China. In recent years, Wendeng has become the major *P. quinquefolius* cultivation area in China. The quality requirements of

### Figure 5.

Total and phosphorylated SRC (A), PI3Kα (B), Akt (C), and ERK (D) in the A549 cells. Cells without a drug treatment were used as the blank group (relative ratio values were set to 1). * indicates *p* < 0.05, ** indicates *p* < 0.01.

3. Discussion

The present study involved the development of an integrated strategy consisting of metabolomics and network pharmacology to explore region-specific biomarkers and their mechanisms in *P. quinquefolius* cultivated in the Wendeng region. Heatmaps were produced, and PCA and OPLS-DA were conducted to highlight the metabolite disparities between the *P. quinquefolius* originating from four production areas. Ginsenosides were previously recognized as the primary bioactive components in the root of *P. quinquefolius* [30,31]. According to the LC–MS/MS analysis, ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were the most abundant biomarkers in the Wendeng species. Moreover, the KEGG pathway and GAD disease enrichment analyses indicated that the compounds were predominantly enriched in lung-cancer-associated pathways. Potential associations between HSP90AA1 (the drug target) and SRC, PIK3CA, and PIK3R1 (the disease targets) were discovered through integrated network pharmacology.

Hsp90 inhibitors exert their inhibitory effects by competitively binding at the ATP binding site of the Hsp90 dimer. They interfere with diverse signaling pathways by destabilizing and attenuating the activity of proteins and are selectively toxic to tumor cells [32,33]. Aberrant activation of the Akt pathway is observed in various human cancers. This activation plays a prominent role in various events associated with tumor progression, such as cell proliferation, invasion, migration, and adhesion [34–36]. Moreover, the Akt pathway is found to cross talk with the MAPK pathway. Previous studies demonstrated that activated SRC recruits the p85 subunit of PI3K, which results in the activation of PI3K and eventually the activation of Akt and extracellular-signal-regulated kinase (ERK) [37]. Thus, it is speculated that phytochemicals inhibiting the phosphorylation of SRC and PI3K could be promising therapeutics for the treatment of lung cancer. Molecular docking and western blotting results reveal that ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were effective binding ligands with Hsp90α and inactivated SRC and PI3K kinase. The interactions between the compounds and the proteins led to the inhibition of the Akt and ERK signaling pathways, which resulted in tumor cell apoptosis.

China has a long history of botanical drug use. According to prior reports, *P. quinquefolius* from Wisconsin (USA) and Ontario (Canada) has been recorded as a “genuine regional drug”. Yanbian is the traditional planting region in China. In recent years, Wendeng has become the major *P. quinquefolius* cultivation area in China. The quality requirements of

### Table 1. MTT assay in A549 cells.

| Concentrations | Cells Viability (%) |
|----------------|---------------------|
| 0.1 mM         | 92.05%              |
| 1.0 mM         | 72.04%              |
| 2.0 mM         | 59.84%              |
| 4.0 mM         | 49.18%              |
| 8.0 mM         | 24.11%              |
| 16.0 mM        | 4.52%               |

The present study involved the development of an integrated strategy consisting of metabolomics and network pharmacology to explore region-specific biomarkers and their mechanisms in *P. quinquefolius* cultivated in the Wendeng region. Heatmaps were produced, and PCA and OPLS-DA were conducted to highlight the metabolite disparities between the *P. quinquefolius* originating from four production areas. Ginsenosides were previously recognized as the primary bioactive components in the root of *P. quinquefolius* [30,31]. According to the LC–MS/MS analysis, ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were the most abundant biomarkers in the Wendeng species. Moreover, the KEGG pathway and GAD disease enrichment analyses indicated that the compounds were predominantly enriched in lung-cancer-associated pathways. Potential associations between HSP90AA1 (the drug target) and SRC, PIK3CA, and PIK3R1 (the disease targets) were discovered through integrated network pharmacology.

Hsp90 inhibitors exert their inhibitory effects by competitively binding at the ATP binding site of the Hsp90 dimer. They interfere with diverse signaling pathways by destabilizing and attenuating the activity of proteins and are selectively toxic to tumor cells [32,33]. Aberrant activation of the Akt pathway is observed in various human cancers. This activation plays a prominent role in various events associated with tumor progression, such as cell proliferation, invasion, migration, and adhesion [34–36]. Moreover, the Akt pathway is found to cross talk with the MAPK pathway. Previous studies demonstrated that activated SRC recruits the p85 subunit of PI3K, which results in the activation of PI3K and eventually the activation of Akt and extracellular-signal-regulated kinase (ERK) [37]. Thus, it is speculated that phytochemicals inhibiting the phosphorylation of SRC and PI3K could be promising therapeutics for the treatment of lung cancer. Molecular docking and western blotting results reveal that ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were effective binding ligands with Hsp90α and inactivated SRC and PI3K kinase. The interactions between the compounds and the proteins led to the inhibition of the Akt and ERK signaling pathways, which resulted in tumor cell apoptosis.

China has a long history of botanical drug use. According to prior reports, *P. quinquefolius* from Wisconsin (USA) and Ontario (Canada) has been recorded as a “genuine regional drug”. Yanbian is the traditional planting region in China. In recent years, Wendeng has become the major *P. quinquefolius* cultivation area in China. The quality requirements of
P. quinquefolius have been identified in the Chinese Pharmacopoeia. Medicinal herbs that meet the required standards can be used for clinical treatment. However, by comparing the medicinal materials from four different regions, the present study demonstrated the potential of region-specific P. quinquefolium components from Wendeng for the treatment of lung adenocarcinoma, which will be helpful for their future use.

4. Materials and Methods

4.1. Samples, Chemicals, and Reagents

Four samples of P. quinquefolius were obtained from Wendeng (Weihai, China), Yanbian (China), Simcoe, ON, (Canada), and Dane County, WI (USA). The botanical origin of the materials was identified by Professor Kechun Liu, Biology Institute of Shandong Academy of Sciences (Jinan, China). Water (Watsons Ltd., Hong Kong, China) and acetonitrile (Tedia Company Inc., Fairfield, OH, USA) were of LC–MS grade. All other chemicals were of analytical grade. Ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were purchased from Shanghai Yuanye Biotechnology Co., Ltd (Shanghai, China). The A549 cells were acquired from the American Type Culture Collection (ATCC) (Rockville, MD, USA).

4.2. LC–MS Assay and Metabolomic Analyses

An amount of 0.5 g of each of the four P. quinquefolius samples was accurately weighed and extracted with 5 mL of methanol for 50 min using ultrasound at 50 °C. The solutions were filtered using 0.45 μm millipore filters for subsequent LC–MS analysis. The gradient conditions for LC–MS involved solvents A (water) and B (acetonitrile) in the following ratios: 5–30% B (0–10 min), 30–70% B (10–30 min), 70–100% B (30–40 min), and 100% B (40–45 min). The flow rate was set at 1 mL/min and the injection volume was 20 μL. Sample ionization was performed by electrospray in the negative mode. The following MS conditions were employed: split ratio of 2:1, drying temperature of 350 °C, drying flow of 12 L/min, nebulizer pressure of 40 psi, capillary voltage of 3500 V, and scan range between 200 and 2000 m/z. The clustering heatmaps were constructed based on the differential metabolites taken from the normalized LC–MS data. A metabolomics method was subsequently used to further investigate the content variation among different groups [38,39]. Variable influence on projection (VIP), p, and p(corr) were applied to identify multiple components with the highest potential as the biomarkers in the OPLS-DA model. Qualitative identification was performed based on high-resolution tandem mass spectrometry (HR-MS/MS) analysis and confirmed by the analysis of standard reference compounds.

4.3. Target Database Construction and Bioinformatics Analysis

Ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were used as the representative chemical components of P. quinquefolius from Wendeng for network pharmacology analysis. The chemical structures were downloaded from the PubChem database (http://pubchem.ncbi.nlm.nih.gov/, accessed on 30 June 2020). The targets related to the active compounds were screened using Swiss Target Prediction (http://www.swisstargetprediction.ch/, accessed on 30 June 2020). DAVID 6.8 (http://david.abcc.ncifcrf.gov/, accessed on 2 July 2020) was employed for the KEGG pathway and GAD disease enrichment analyses of the targets [40,41]. According to the enrichment scores obtained from the bioinformatics analysis, the target genes associated with the “lung adenocarcinoma” disease name were collected using GeneCards (https://www.genecards.org/, accessed on 2 July 2020). The candidate targets were inputted to String 11.0 (https://string-db.org/, accessed on 2 July 2020) to obtain the relevant information on protein interactions. The active compounds and their potential target proteins were integrated to construct a network employing Cytoscape 3.6.1.

4.4. Molecular Docking

Based on the compound–target network construction and analysis, molecular docking was used to confirm the interactions between the ligands and obtained targets. The 3D
structures of ginsenoside Rb3, notoginsenoside R1, and ginsenoside Rc were constructed and stored as PDB files using the PubChem database. The crystallographic structure of the human Hsp90α protein (1.7 Å, HSP90AA1) was downloaded from the Protein Data Bank (PDB) (https://www.rcsb.org/, accessed on 15 July 2020). Each compound was docked into the candidate target using the AutoDock software relying on the genetic algorithm with default parameters [42,43]. Following docking, the affinity scores for the protein–ligand complexes were analyzed, and the results were visualized using the PyMol software [44].

4.5. Western Blot Analysis

Apoptosis in A549 cells was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were treated with ginsenoside Rb3 (2 mM), notoginsenoside R1 (1 mM), and ginsenoside Rc (2.5 mM) for 4 h. The cells were then lysed in the RIPA buffer (cat no. P0013B, Beyotime, Shanghai, China), and the expressions of apoptosis-related proteins were evaluated [45,46]. Briefly, the proteins were resolved via 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene fluoride (PVDF) membranes, and probed with primary antibodies and horseradish peroxidase-conjugated secondary antibodies. The blots were developed using an enhanced chemiluminescence (ECL) kit (cat no. K-12043-D10, Servicebio, Wuhan, China), and the target protein expressions were determined relative to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

The following antibodies were used: anti-SRC (1:1000, cat no. #2109, CST, Danvers, MA, USA), anti-p-SRC (1:1000, cat no. #6943, CST), anti-PI3Kα (1:1000, cat no. #4249, CST), anti-p-PI3Kα (1:1000, cat no. #4228, CST), anti-Akt (1:1000, cat no. #4691, CST), anti-p-Akt (1:1000, cat no. #4060, CST), anti-ERK (1:1000, cat no. #4695, CST), anti-p-ERK (1:1000, cat no. #9101, CST), anti-GAPDH (1:5000, cat no. ATPA00013Rb, Atagenix, Wuhan, China), HRP-conjugated goat anti-rabbit IgG (1:5000, cat no. SA00001-2, Proteintech, Rosemont, IL, USA), and HRP-conjugated goat anti-mouse IgG (1:5000, cat no. SA00001-1, Proteintech, Rosemont, IL, USA).

Supplementary Materials: The following are available online: Figure S1, LC–Q–TOF-MS chromatograms of *P. quinquefolius* from Wendeng (six samples); Figure S2, LC–Q–TOF-MS chromatograms of *P. quinquefolius* from Yanbian (six samples); Figure S3, LC–Q–TOF-MS chromatograms of *P. quinquefolius* from Ontario (six samples); Figure S4, LC–Q–TOF-MS chromatograms of *P. quinquefolius* from Wisconsin (six samples); Figure S5, The retention times for the three biomarkers in Wendeng species (1) Ginsenoside Rb3 (2) Notoginsenoside R1 (3) Ginsenoside Rc; Figure S6, The compound-target network. The yellow node represents the most important targets. (Potential compounds: blue rectangles; Drug targets: green triangles; Disease targets: brown circles). Table S1, 30 biomarkers of *P. quinquefolius* from the Wendeng region in OPLS-DA analysis; Table S2, KEGG pathway information for the three compounds; Table S3, Topological parameters for the key targets; Table S4, Binding energy calculation results.

Author Contributions: Conceptualization, investigation, writing of the original manuscript, X.Z.; Methodology, data curation, review, editing of the manuscript, L.H., S.Z. and X.L.; Conceptualization, formal analysis, data curation, P.L. and M.Z.; Investigation, resources, J.C.; Methodology, data curation, L.W.; Project administration, Y.Z.; Supervision, funding acquisition, P.T. and K.L. All authors have read and agreed to the published version of the manuscript.

Funding: This study was financially supported by the Major Scientific and Technological Innovation Project of Shandong Province (grant number, 2019JZZY020905), the Key R&D Program of Shandong Province (grant number, 2019YSP017), and the Science, Education and Industry Integration Innovation Pilot Project of the Qilu University of Technology (Shandong Academy of Sciences) (grant number: 2020KJC-ZD08).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare that there are no conflict of interest.

Sample Availability: Not applicable.

References
1. Chen, C.Y.O.; Ribaya-Mercado, J.D.; McKay, D.L.; Croom, E.; Blumberg, J.B. Differential antioxidant and quinone reductase inducing activity of American, Asian, and Siberian ginseng. *Food Chem.* 2010, 119, 445–451. [CrossRef]
2. Ghosh, R.; Bryant, D.L.; Farone, A.L. *Panax quinquefolius* (North American Ginseng) polysaccharides as immunomodulators: Current research status and future directions. *Molecules* 2020, 25, 5854. [CrossRef] [PubMed]
3. Wan, J.Y.; Fan, Y.; Yu, Q.T.; Ge, Y.Z.; Yan, C.P.; Aloaga, R.N.; Li, P.; Ma, Z.H.; Qi, L.W. Integrated evaluation of malonyl ginsenosides, amino acids and polysaccharides in fresh and processed ginseng. *J. Pharm. Biomed.* 2015, 107, 89–97. [CrossRef] [PubMed]
4. Schlag, E.M.; McIntosh, M.S. Ginsenoside content and variation among and within American ginseng (*Panax quinquefolius* L.) populations. *Phytochemistry* 2006, 67, 1510–1519. [CrossRef] [PubMed]
5. Li, L.L.; Wang, D.J.; Sun, C.L.; Li, Y.; Lu, H.; Wang, X. Comprehensive lipidome and metabolome profiling investigations of *Panax quinquefolius* and application in different growing regions using liquid chromatography coupled with mass spectrometry. *J. Agric. Food Chem.* 2021, 69, 6710–6719. [CrossRef]
6. Yang, Y.G.; Ju, Z.C.; Yang, Y.B.; Zhang, Y.H.; Yang, L.; Wang, Z.T. Phytochemical analysis of *Panax* species: A review. *J. Ginseng Res.* 2021, 1, 1–21. [CrossRef]
7. Barton, D.L.; Liu, H.; Dakhil, S.R.; Linquist, B.; Sloan, J.A.; McGinn, T.W.; Stella, P.J.; Seeger, G.R.; Sood, A.; et al. *Wisconsin ginseng* (*Panax quinquefolius*) to improve cancer-related fatigue: A randomized, double-blind trial. *N07C2*. *J. Natl. Cancer Inst.* 2013, 105, 1230–1238.
8. Chen, C.F.; Chiou, W.F.; Zhang, J.T. Comparison of the pharmacological effects of *Panax ginseng* and *Panax quinquefolium*. *Acta Pharm. Sin.* 2008, 29, 1103–1108. [CrossRef]
9. Kochan, E.; Nowak, A.; Zaklos-Szyda, M.; Szczeruca, D.; Szymarska, G.; Motyl, I. *Panax quinquefolium* L. ginsenosides from hairy root cultures and their clones exert cytotoxic, genotoxic and pro-apoptotic activity towards human colon adenocarcinoma cell line caco-2. *Molecules* 2020, 25, 2262. [CrossRef]
10. Qu, C.L.; Bai, Y.P.; Jin, X.Q.; Wang, Y.T.; Zhang, K.; You, J.Y.; Zhang, H.Q. Study on ginsenosides in different parts and ages of *Panax quinquefolius* L. *Food Chem.* 2009, 115, 340–346. [CrossRef]
11. Sun, S.; Qi, L.W.; Du, G.J.; Mehendale, S.R.; Wang, C.Z.; Yuan, C.S. Red notoginseng: Higher ginsenoside content and stronger anticancer potential than Asian and American ginseng. *Food Chem.* 2011, 125, 1299–1305. [CrossRef]
12. He, S.; Lyu, F.; Lou, L.X.; Liu, L.; Li, S.L.; Jakowitsch, J.; Ma, Y. Anti-tumor activities of *Panax quinquefolius* saponins and potent-tential biomarkers in prostate cancer. *J. Ginseng Res.* 2021, 45, 273–286. [CrossRef] [PubMed]
13. Zhang, X.M.; Bi, Y.M.; Li, J.F.; Shao, H.H.; Jiao, X.L.; Gao, W.W. First report of root rot caused by *Fusarium armeniacum* on American ginseng in China. *Plant. Dis.* 2021, 105, 1223. [CrossRef] [PubMed]
14. Li, F.; Lv, C.N.; Li, Q.; Wang, J.; Song, D.; Liu, P.P.; Zhang, D.D.; Lu, J.C. Chemical and bioactive comparison of flowers of *Panax ginseng* Meyer, *Panax quinquefolium* L. and *Panax notoginseng* Burk. *J. Gins Res.* 2017, 41, 487–495. [CrossRef] [PubMed]
15. Ligor, T.; Ludwiczuk, A.; Wolski, T.; Buszewski, B. Isolation and determination of ginsenosides in American ginseng leaves and root extracts by LC–MS. *Anal. Bioanal. Chem.* 2005, 383, 1098–1105. [CrossRef]
16. Wang, H.D.; Zhang, C.X.; Zuo, T.T.; Li, W.W.; Jia, L.; Wang, X.Y.; Qian, Y.X.; Guo, D.A.; Yang, W.Z. In-depth profiling, characterization, and comparison of the ginsenosides among three different parts (the root, stem leaf, and flower bud) of *Panax quinquefolius* L. by ultra-high-performance liquid chromatography/quadrupole-Orbitrap mass spectrometry. *Anal. Bioanal. Chem.* 2019, 411, 7817–7829. [CrossRef] [PubMed]
17. Wang, J.; Liu, H.; Gao, W.Y.; Zhang, L.M. Comparison of ginsenoside composition in native roots and cultured callus cells of *Panax quinquefolium* L. *Acta Physiol. Plant.* 2013, 35, 1363–1366. [CrossRef]
18. Li, J.; Zuo, T.T.; Zhang, C.X.; Li, W.W.; Wang, H.D.; Hu, Y.; Wang, X.Y.; Qian, Y.X.; Yang, W.Z.; Yu, H.S. Simultaneous profiling and holistic comparison of the metabolomes among the flower buds of *Panax ginseng*, *Panax quinquefolius*, and *Panax notoginseng* by UHPLC/IM-QTOF-HDMSE-based metabolomics analysis. *Molecules* 2019, 24, 2188.
19. Xing, J.J.; Hou, J.G.; Liu, Y.; Zhang, R.B.; Jiang, S.; Ren, S.; Wang, Y.P.; Shen, Q.; Li, W.; Li, X.D.; et al. Supplementation of saponins from leaves of *Panax quinquefolius* mitigates cisplatin-evoked cardiotoxicity via inhibiting oxidative stress-associated inflammation and apoptosis in mice. *Antioxidants* 2019, 8, 347. [CrossRef]
20. Han, B.J.; Zhang, Z.; Xie, Y.X.; Hu, X.Q.; Wang, H.B.; Xia, W.; Wang, Y.L.; Li, H.Y.; Wang, Y.C.; Sun, H.Z. Multi-omics and temporal dynamics profiling reveal disruption of central metabolism in *Helicobacter pylori* on bismuth treatment. *Chem. Sci.* 2018, 9, 7488–7497. [CrossRef] [PubMed]
21. Liu, J.; Liu, Y.; Wang, Y.; Abozeid, A.; Zu, Y.G.; Tang, Z.H. The integration of GC–MS and LC–MS to assay the metabolomics profiling in *Panax ginseng* and *Panax quinquefolius* reveals a tissue- and species-specific connectivity of primary metabolites and ginsenosides accumulation. *J. Pharm. Biomed.* 2017, 135, 176–185. [CrossRef] [PubMed]
22. Wang, H.Y.; Hua, H.Y.; Liu, X.Y.; Liu, J.H.; Yu, B.Y. In vitro biotransformation of red ginseng extract by human intestinal microflora: Metabolites identification and metabolic profile elucidation using LC-Q-TOF/MS. *J. Pharm. Biomed.* 2014, 98, 296–306. [CrossRef] [PubMed]
23. Xiong, H.; Zhang, A.H.; Zhao, Q.Q.; Yan, G.L.; Sun, H.; Wang, X.J. Discovery of quality-marker ingredients of *Panax quinquefolius* driven by high-throughput cheminformatics approach. *Phytomedicine* 2020, 74, 152928. [CrossRef]

24. Calvert, S.; Tacutu, R.; Sharifi, S.; Teixeira, R.; Ghosh, P.; Magalhaes, J.P. A network pharmacology approach reveals new candidate caloric restriction mimetics in *C. elegans*. *Aging Cell* 2016, 15, 256–266. [CrossRef]

25. Gao, L.; Wang, X.D.; Niu, Y.Y.; Duan, D.D.; Yang, X.; Hao, J.; Zhu, C.H.; Chen, D.; Wang, K.X.; Qin, X.M.; et al. Molecular targets of Chinese herbs: A clinical study of hepatoma based on network pharmacology. *Sci. Rep.* 2016, 6, 24944. [CrossRef]

26. Tan, Y.S.; Li, F.; Lv, Y.N.; Zhai, K.F.; Chai, C.Z.; Kou, J.P.; Yu, B.Y. Study on the multi-targets mechanism of YiQiFuMai powder injection on cardio-cerebral ischemic diseases based on network pharmacology. *J. Proteom. Comput. Biol.* 2014, 1, 9.

27. Gazdar, A.F.; Bunn, P.A.; Minna, J.D. Small-cell lung cancer: What we know, what we need to know and the path forward. *Nat. Rev. Cancer* 2017, 17, 725–737.

28. Mcintyre, A.; Ganti, A.K. Lung cancer-A global perspective. *J. Surg Oncol.* 2017, 115, 550–554. [CrossRef]

29. Triba, M.N.; Moyec, L.L.; Amathieu, R.; Goossens, C.; Bouchemal, N.; Nahon, P.; Rutledge, D.N.; Savarin, P. PLS/OPLS models in metabolomics: The impact of permutation of dataset rows on the K-fold cross-validation quality parameters. *Mol. Biosyst.* 2014, 11, 13–19. [CrossRef] [PubMed]

30. Ma, X.Q.; Xiao, H.B.; Liang, X.M. Identification of ginsenosides in *Panax quinquefolium* by LC–MS. *Chromatographia* 2006, 64, 31–36. [CrossRef]

31. Jega, J.; Jeong, E.J.; Yang, M.H. A review of the different methods applied in ginsenoside extraction from *Panax ginseng* and *Panax quinquefolius* roots. *Nat. Prod. Commun.* 2019, 14, 1934578X1986839. [CrossRef]

32. Gupta, S.D. Hsp90 flexibility and development of its inhibitors for the treatment of cancer. *Curr. Chem. Biol.* 2018, 12, 53–64. [CrossRef]

33. Solit, D.B.; Rosen, N. Hsp90: A novel target for cancer therapy. *Curr. Top. Med. Chem.* 2006, 6, 1205–1214. [CrossRef]

34. Crosbie, P.A.J.; Crosbie, E.J.; Aspinall-O’Dea, M.; Walker, M.; Harrison, R.; Pernemalm, M.; Shah, R.; Joseph, L.; Booton, R.; Pierce, A.; et al. ERK and AKT phosphorylation status in lung cancer and emphysema using nanopillary isoelectric focusing. *BMJ Open Respir. Res.* 2016, 3, e000114. [CrossRef]

35. Ebi, H.; Costa, C.; Faber, A.C.; Nishtala, M.; Kotani, H.; Juric, D.; Pelle, P.D.; Song, Y.C.; Yano, S.J.; Mino-Kenudson, M.; et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GFP, P-Rex1. *Proc. Natl. Acad. Sci. USA* 2013, 110, 21124–21129. [CrossRef] [PubMed]

36. Fan, D.P.; Zhang, Y.M.; Hu, X.C.; Li, J.J.; Zhang, W. Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine. *Int. J. Clin. Exp. Pathol.* 2014, 7, 134–143.

37. Koga, F.; Xu, W.P.; Karpova, T.S.; McNally, J.G.; Baron, R.; Neckers, L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. *Proc. Natl. Acad. Sci. USA* 2006, 103, 11318–11322. [CrossRef] [PubMed]

38. Zhang, X.M.; Han, L.W.; Zhang, S.S.; Li, X.B.; He, Q.X.; Han, J.; Wang, X.M.; Liu, K.C. Targeted discovery and identification of novel nucleoside biomarkers in *Apostichopus japonicus* viscer using metabolomics. *Nucl. Nucl. Nucl. Acids Sci.* 2017, 14, 1934578X1986839. [CrossRef]

39. Zhang, X.M.; Shi, Y.P.; Wang, L.Z.; Li, X.B.; Zhang, S.S.; Wang, X.M.; Jin, M.; Hsiao, C.D.; Lin, H.W.; Han, L.W.; et al. Metabolomics for biomarker discovery in fermented black garlic and potential bioprotective responses against cardiovascular diseases. *J. Agric. Food Chem.* 2019, 67, 12191–12198. [CrossRef] [PubMed]

40. Sun, X.; Dai, Y.S.; Tan, G.L.; Liu, Y.Q.; Li, N. Integration analysis of m6A-SNPs and eQTLs associated with sepsis reveals platelet degranulation and *Staphylococcus aureus* infection are mediated by m6A mRNA methylation. *Front. Genet.* 2020, 11, 7. [CrossRef] [PubMed]

41. Li, Y.; Li, W.G.; Zeng, X.M.; Tang, X.M.; Zhang, S.; Zhong, F.Y.; Peng, X.N.; Zhong, Y.; Rosol, T.J.; Deng, X.Y.; et al. The role of microRNA-148a and downstream DLGAP1 on the molecular regulation and tumor progression on human glioblastoma. *Oncogene* 2019, 38, 7234–7248. [CrossRef] [PubMed]

42. Helgren, T.R.; Hagen, T.J. Demonstration of AutoDock as an educational tool for drug discovery. *J. Chem. Educ* 2017, 94, 345–349. [CrossRef] [PubMed]

43. Tiwari, A.; Saxena, S.; Pant, A.B.; Srivastava, P. Protein-ligand interaction studies of retinol-binding protein 3 with herbal molecules using AutoDock for the management of Eales’ disease. *J. Ocul. Biol. Inf.* 2012, 5, 40–43. [CrossRef] [PubMed]

44. Mothay, D.; Ramesh, K.V. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. *VirusDisease* 2020, 31, 194–199. [CrossRef]

45. Chan, Q.K.Y.; Lam, H.M.; Ng, C.F.; Lee, A.Y.Y.; Chan, E.S.Y.; Ng, H.K.; Ho, S.M.; Lau, K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest. *Cell Death Differ.* 2010, 17, 1511–1523. [CrossRef]

46. Sun, Y.; Du, C.; Wang, B.; Zhang, Y.; Liu, X.; Ren, G. Upregulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. *BioChem. Bioph Res.* 2014, 450, 1–6. [CrossRef]